Targeting Cancer Stem Cells in Cholangiocarcinoma (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2020 May 30

PMID 32468022

Citations 13

Authors

Nicole A McGrath

Jianyang Fu

Sophie Z Gu

Changqing Xie

Affiliations

Soon will be listed here.

Abstract

The incidence of cholangiocarcinoma has been increasing steadily over the past 50 years, but the survival rates remained low due to the disease being highly resistant to non‑surgical treatment interventions. Cancer stem cell markers are expressed in cholangiocarcinoma, suggesting that they serve a significant role in the physiology of the disease. Cancer stem cells are frequently implicated in tumor relapse and acquired resistance to a number of therapeutic strategies, including chemotherapy, radiation and immune checkpoint inhibitors. Novel targeted therapies to eradicate cancer stem cells may assist in overcoming treatment resistance in cholangiocarcinoma and reduce the rates of relapse and recurrence. Several signaling pathways have been previously documented to regulate the development and survival of cancer stem cells, including Notch, janus kinase/STAT, Hippo/yes‑associated protein 1 (YAP1), Wnt and Hedgehog signaling. Although pharmacological agents have been developed to target these pathways, only modest effects were reported in clinical trials. The Hippo/YAP1 signaling pathway has come to the forefront in the field of cancer stem cell research due to its reported involvement in epithelium‑mesenchymal transition, cell adhesion, organogenesis and tumorigenesis. In the present article, recent findings in terms of cancer stem cell research in cholangiocarcinoma were reviewed, where the potential therapeutic targeting of cancer stem cells in this disease was discussed.

Citing Articles

A live single-cell reporter system reveals drug-induced plasticity of a cancer stem cell-like population in cholangiocarcinoma.

Kongtanawanich K, Prasopporn S, Jamnongsong S, Thongsin N, Payungwong T, Okada S Sci Rep. 2024; 14(1):22619.

PMID: 39349745 PMC: 11442615. DOI: 10.1038/s41598-024-73581-8.

MiR-582 Down-Regulates Lissencephaly-1 () via P-Akt and MMP-2 to Inhibit Cholangiocarcinoma Cell Proliferation and Invasion.

Liu G, Li T, Ma L, Wang J, Yin Z Iran J Biotechnol. 2024; 20(4):e3136.

PMID: 38344318 PMC: 10858362. DOI: 10.30498/ijb.2022.301092.3136.

LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2/STAT3 signaling.

Yu S, Gao X, Liu S, Sha X, Zhang S, Zhang X Cancer Gene Ther. 2024; 31(4):552-561.

PMID: 38267625 DOI: 10.1038/s41417-024-00726-2.

Single-cell RNA sequencing reveals cancer stem-like cells and dynamics in tumor microenvironment during cholangiocarcinoma progression.

Golino J, Bian J, Wang X, Fu J, Zhu X, Yeo J Front Cell Dev Biol. 2023; 11:1250215.

PMID: 38020927 PMC: 10667919. DOI: 10.3389/fcell.2023.1250215.

HELLS modulates the stemness of intrahepatic cholangiocarcinoma through promoting senescence-associated secretory phenotype.

Du X, Zhang X, Qi Z, Zeng Z, Xu Y, Yu Z Comput Struct Biotechnol J. 2023; 21:5174-5185.

PMID: 37920816 PMC: 10618119. DOI: 10.1016/j.csbj.2023.09.020.

References

Luo Y, Dallaglio K, Chen Y, Robinson W, Robinson S, McCarter M . ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells. 2012; 30(10):2100-13. PMC: 3448863. DOI: 10.1002/stem.1193. View

Li F, Xu Y, Liu B, Singh P, Zhao W, Jin J . YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2018; 25(7):2264-2277. DOI: 10.1158/1078-0432.CCR-18-1029. View

Ko A, LoConte N, Tempero M, Walker E, Kelley R, Lewis S . A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2015; 45(3):370-5. PMC: 5908466. DOI: 10.1097/MPA.0000000000000458. View

Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H . CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012; 72(13):3414-23. DOI: 10.1158/0008-5472.CAN-12-0299. View

Park J, Oh D, Hsu C, Chen J, Chen L, Orlando M . Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat. 2015; 47(3):343-61. PMC: 4509359. DOI: 10.4143/crt.2014.308. View

Fan B, Malato Y, Calvisi D, Naqvi S, Razumilava N, Ribback S . Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122(8):2911-5. PMC: 3408746. DOI: 10.1172/JCI63212. View

Takaishi S, Okumura T, Tu S, Wang S, Shibata W, Vigneshwaran R . Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009; 27(5):1006-20. PMC: 2746367. DOI: 10.1002/stem.30. View

Clara J, Monge C, Yang Y, Takebe N . Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2019; 17(4):204-232. DOI: 10.1038/s41571-019-0293-2. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

10.

Pietras A, Katz A, Ekstrom E, Wee B, Halliday J, Pitter K . Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014; 14(3):357-69. PMC: 3999042. DOI: 10.1016/j.stem.2014.01.005. View

11.

Bhuria V, Xing J, Scholta T, Bui K, Nguyen M, Malek N . Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma. Exp Cell Res. 2019; 385(2):111671. DOI: 10.1016/j.yexcr.2019.111671. View

12.

Bora-Singhal N, Nguyen J, Schaal C, Perumal D, Singh S, Coppola D . YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells. Stem Cells. 2015; 33(6):1705-18. PMC: 4441573. DOI: 10.1002/stem.1993. View

13.

Lingala S, Cui Y, Chen X, Ruebner B, Qian X, Zern M . Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010; 89(1):27-35. PMC: 2900434. DOI: 10.1016/j.yexmp.2010.05.005. View

14.

Yan J, De Melo J, Cutz J, Aziz T, Tang D . Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis. Br J Cancer. 2014; 110(10):2593-603. PMC: 4021532. DOI: 10.1038/bjc.2014.201. View

15.

Hoei-Hansen C, Almstrup K, Nielsen J, Brask Sonne S, Graem N, Skakkebaek N . Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology. 2005; 47(1):48-56. DOI: 10.1111/j.1365-2559.2005.02182.x. View

16.

Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S . Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer. 2011; 130(1):29-39. PMC: 3164893. DOI: 10.1002/ijc.25967. View

17.

Lee K, Lee K, Jung H, Yi N, Lee K, Suh K . The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas. BMC Cancer. 2017; 17(1):441. PMC: 5481924. DOI: 10.1186/s12885-017-3431-1. View

18.

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M . CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014; 14(3):342-56. DOI: 10.1016/j.stem.2014.01.009. View

19.

Song S, Xie M, Scott A, Jin J, Ma L, Dong X . A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer Ther. 2017; 17(2):443-454. PMC: 5805581. DOI: 10.1158/1535-7163.MCT-17-0560. View

20.

Chou Y, Lee C, Hsiao S, Lin S, Lin S, Chung C . The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem Cells. 2013; 31(12):2607-19. DOI: 10.1002/stem.1518. View